Funded with Support from

This paper describes the investigation, response and successful containment of an adenovirus outbreak in a NICU associated with contaminated handheld ophthalmologic equipment used during retinopathy of prematurity screening.

Dr. Tahira Scholle demonstrates the administration of a subretinal injection of Luxturna (voretigene neparvovec-ryzyl), the first FDA-approved gene therapy for inherited retinal disease.

This prospective, multicenter study compared ophthalmoscopy with telemedicine for diagnosing retinopathy of prematurity (ROP).

Retinoblastoma (Rb) is a primary intraocular cancer that develops in the eyes of young children most often under the age of 5 years.Access to the acueous humor AH of eyes with active Rb has enabled the first-ever genetic analyses of Rb tumors in situ (ie, without enucleation). This is the first time that retinoblastoma tumor DNA has been available from eyes before they were enucleated. [Please also see the interview with Dr. Berry at https://www.aao.org/interview/aqueous-humor-biopsy-retinoblastoma.]

Dr. Janice Law makes the case that there are clinical advantages to using bevacizumab including the larger molecule more easily staying in the eye and a longer half-life, which prolongs its effect.

Dr. David Morrison makes the case that, although cost is an issue when considering the use of ranibizumab, there are many benefits to its use.

A white female who presented at 7 months for nystagmus has been followed over a 16-year period and has had 2 examinations under anesthesia confirming her diagnosis of achromatopsia.

This retrospective, longitudinal study assessed the rate of ophthalmic examinations among youths with diabetes, specifically to monitor screening for diabetic retinopathy (DR).

In this webinar presentation from AAPOS, Drs.Phelps, Quinn, Lee, and Chiang present new indications in the treatment and management of retinopathy of prematurity.